| 98.42 1.23 (1.27%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 116.29 | 1-year : | 135.82 |
| Resists | First : | 99.56 | Second : | 116.29 |
| Pivot price | 93.79 |
|||
| Supports | First : | 87.91 | Second : | 80.72 |
| MAs | MA(5) : | 97 |
MA(20) : | 91.77 |
| MA(100) : | 69.96 |
MA(250) : | 43.83 |
|
| MACD | MACD : | 4.2 |
Signal : | 4.1 |
| %K %D | K(14,3) : | 92.1 |
D(3) : | 88.3 |
| RSI | RSI(14): 62.9 |
|||
| 52-week | High : | 99.56 | Low : | 12.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ORKA ] has closed below upper band by 13.1%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 99.59 - 100.29 | 100.29 - 100.83 |
| Low: | 95.09 - 95.83 | 95.83 - 96.4 |
| Close: | 97.45 - 98.6 | 98.6 - 99.49 |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Mon, 03 Aug 2026
Oruka Therapeutics Is Priced For Perfection - It’s Time To Cash Out (NASDAQ:ORKA) - Seeking Alpha
Sat, 01 Aug 2026
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Fri, 24 Jul 2026
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
Fri, 17 Jul 2026
ORKA Stock Climbs As Traders Track Strong Cash Runway - StocksToTrade
Fri, 12 Jun 2026
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wed, 10 Jun 2026
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 95.4 (%) |
| Shares Short | 8,830 (K) |
| Shares Short P.Month | 6,900 (K) |
| EPS | -1.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -27.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -51 |
| PEG Ratio | 0 |
| Price to Book value | 10.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -65.29 |
| Dividend | 19.36 |
| Forward Dividend | 0 |
| Dividend Yield | 19.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|